What are the side effects of ARA-290 (Cibinetide)?
The most commonly reported ARA-290 (Cibinetide) side effects are generally well tolerated, rare: mild headache, injection-site reaction. Most are mild and tend to be dose dependent. It is generally avoided with pregnancy / nursing. Human clinical evidence for ARA-290 (Cibinetide) is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported ARA-290 (Cibinetide) side effects
- Generally well tolerated
- Rare: mild headache
- Injection-site reaction
Who should avoid it
- Pregnancy / nursing
- Active malignancy, limited data
Bloodwork worth tracking
- CBC (no measurable RBC effect, but cheap monitoring if running long)
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Last updated 2026-06-06.